CAVU Biotherapies

CAVU Biotherapies has nimble patented immunotherapy platform that can create cellular immunotherapies to treat cancer, autoimmune diseases, and allergies. Cancer is our first indication with our Autologous Prescription Product already out in the market place. CAVU intends to have an immunotherapy for atopic dermatitis in clinical trial in 18 months. CAVU also has a potential prognostic/diagnostic test with our IHAV. The IHAV is in beta testing currently with a large amount of data amassed. Our final product is SafeDePawsit, a cryobanking service to save back your pet's healthy immune system BEFORE disease strikes!